Ubs Group Ag 4 D Molecular Therapeutics, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 374,190 shares of FDMT stock, worth $7.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

374,190

Previous 86,051 334.85%

Holding current value

$7.8 Million

Previous $1.74 Million 583.94%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$17.03 - $35.87 $4.91 Million - $10.3 Million	288,139 Added 334.85%	374,190 $11.9 Million
Q4 2023 Feb 09, 2024	BUY	$9.76 - $21.25 $401,663 - $874,522	41,154 Added 91.66%	86,051 $1.74 Million
Q3 2023 Nov 09, 2023	SELL	$12.64 - $19.76 $113,165 - $176,911	-8,953 Reduced 16.63%	44,897 $571,000
Q2 2023 Aug 11, 2023	BUY	$15.16 - $23.26 $21,997 - $33,750	1,451 Added 2.77%	53,850 $973,000
Q1 2023 May 12, 2023	BUY	$15.45 - $23.19 $180,316 - $270,650	11,671 Added 28.66%	52,399 $900,000

Q4 2022 Feb 08, 2023	BUY	$6.85 - $25.46 $278,986 - $1.04 Million	40,728 New	40,728 $904,000
Q2 2022 Aug 10, 2022	SELL	$5.68 - $15.99 $398,730 - $1.12 Million	-70,199 Reduced 99.95%	35 $0
Q1 2022 May 16, 2022	BUY	$13.16 - $22.64 $11,633 - $20,013	884 Added 1.27%	70,234 $1.06 Million
Q4 2021 Feb 14, 2022	BUY	$19.56 - $32.94 $1.33 Million - $2.24 Million	68,094 Added 5421.5%	69,350 $1.52 Million
Q3 2021 Nov 15, 2021	BUY	$22.73 - $36.04 $28,548 - $45,266	1,256 New	1,256 $34,000
Q2 2021 Aug 13, 2021	SELL	$22.2 - $42.29 $457,142 - $870,835	-20,592 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$35.94 - $52.67 $740,076 - $1.08 Million	20,592 New	20,592 $893,000

Others Institutions Holding FDMT

# of Institutions

157

Shares Held

50.3M

Call Options Held

718K

Put Options Held

370K

View Full List

About 4D Molecular Therapeutics, Inc.

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $675M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

More about FDMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account